Cogent Biosciences is a biotechnology company that is developing precision therapies for genetically defined diseases. Their lead product candidate, CGT9486, inhibits the KIT D816V mutation found in systemic mastocytosis and other mutations in KIT exon 17 in gastrointestinal stromal tumor patients. The company has a licensing agreement with Plexxikon Inc. and was previously known as Unum Therapeutics.